一般社団法人 日本感染症学会 第89回総会資料
|
|
|
- ひろじ ごみぶち
- 7 years ago
- Views:
Transcription
1
2 Longitudinal surveillance of Haemophilus influenzae isolates from pediatric patients with meningitis throughout Japan, Journal of Infection and Chemotherapy Vol.19No.1 p34-41kimiko Ubukata Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up AIDS 2014; 28: Nishijima Takeshi 14 Clostridium difficile
3
4 β
5
6
7
8
9
10
11
12 審 議 事 項
13
14
Vol.9No.22012
6 21 2 21 8 7 118 Vol.9No.22012 6 2 3 1 10 10 1 13 1 13 1320 1956 1961 1977 21 8 1979 1981 1982 2011 2003 20062011 Vol.9No.22012 119 1 23 8 21 1 1 24 20 22 18 8 120 Vol.9No.22012 2 9 1953 2 1979 2 2 1982
P1-1 P1-2 P1-3 P1-4 P1-5 P1-6 P3-1 P3-2 P3-3 P3-4 P3-5 P3-6 P5-1 P5-2 P5-3 P5-4 P5-5 P5-6 P7-1 P7-2 P7-3 P7-4 P7-5 P7-6 P9-1 P9-2 P9-3 P9-4 P9-5 P9-6 P11-1 P11-2 P11-3 P11-4 P13-1 P13-2 P13-3 P13-4 P13-5
JAPAN MARKETING JOURNAL 113 Vol.29 No.12009
JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 JAPAN MARKETING JOURNAL 113 Vol.29 No.12009 Vol.29 No.12009 JAPAN MARKETING
JAPAN MARKETING JOURNAL 111 Vol.28 No.32008
Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING JOURNAL 111 Vol.28 No.32008 JAPAN MARKETING
JAPAN MARKETING JOURNAL 110 Vol.28 No.22008
Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING
日本糖尿病学会誌第58巻第7号
l l l l β μ l l l l l l α l l l l l l l μ l l l α l l l l l μ l l l l l l l l l l l l l μ l l l l l β l μ l μ l μ l μ l l l l l μ l l l μ l l μ l l l α α l μ l l μ l α l μ l α l l l μ l l l μ l l μ l
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
JAPAN MARKETING JOURNAL 123 Vol.31 No.32012
Japan Marketing Academy JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN
JAPAN MARKETING JOURNAL 115 Vol.29 No.32010
Japan Marketing Academy JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN MARKETING JOURNAL 115 Vol.29 No.32010 JAPAN
JAPAN MARKETING JOURNAL 110 Vol.28 No.22008
JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110 Vol.28 No.22008 JAPAN MARKETING JOURNAL 110
untitled
8 2012211 2012 8 2012211 TEL048-758-1811FAX048-758-1818 E-mailhagiwara.shinichiro@pref.saitama.lg.jp 8 7 5 101 0003 2 6 2 03 3230 2831 7F 703 704 707 705 8 1000 1005 1 1010 1050 O-01 Yersinia pseudotuberculosis
JAPAN MARKETING JOURNAL 123 Vol.31 No.32012
Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING JOURNAL 123 Vol.31 No.32012 JAPAN MARKETING
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
1 2 4 6 8 10 12 20 22 26 28 30 34 36 42 44 46 48 50 54 56 58 60 62 64 2 3 4 5 6 12,403 3,253 26.2% 3,539 28.5% 1,934 15.6% 2,283 18.4% 487 3.9% 907 7.3% 7 OSAKA 810,000 1102 644 54 135 976 32,000 Amazon.co.jp
木材利用における林野庁施策の動向１
10 1931 10 1050 H21 2,900 45.9% (14%) 253 4.0% 6,321m 3 (100%) 816 12.9% (21%) m 3 2,351 37.2% (41%) 8130 598 1,024m 3 8248% 198m 3 58 7% 1,758m 3 55% 48%+7%=55% 22 519 26 10 4 1 3 Vol53No.4,1998
４月号 学会特集号 １２２２４７／１６）一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
「諸雑公文書」整理の中間報告
30 10 3 from to 10 from to ( ) ( ) 20 20 20 20 20 35 8 39 11 41 10 41 9 41 7 43 13 41 11 42 7 42 11 41 7 42 10 4 4 8 4 30 10 ( ) ( ) 17 23 5 11 5 8 8 11 11 13 14 15 16 17 121 767 1,225 2.9 18.7 29.8 3.9
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
目次.PDF
平 成 18 年 第 1 回 定 例 会 新 上 五 島 町 議 会 会 議 録 平 成 18 年 3 月 7 日 ~3 月 20 日 (14 日 間 ) 新 上 五 島 町 議 会 2 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 1 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
★索引.indb
S 703 S 704 S 705 S 706 S 707 S 708 S 709 S 710 S 711 S 712 S 713 S 714 S 715 S 716 S 717 S 718 20 4 15 Japanese Journal of Medical Ultrasonics 35 101 0063 2 23 1 6 F The Japan Society of Ultrasonics in
ｋｎｓｐ－０９／ｋｙ０８２８４４１３９０００００５９４２
1 4 17 10 : 50 11 : 50 2 4 17 15 : 00 16 : 00 1 4 17 16 : 00 17 : 00 2 4 18 10 : 50 11 : 50 1 4 17 8:50 9:20 2 4 17 9:20 9:50 3 4 17 9:50 10 : 20 4 4 17 10 : 20 10 : 50 5 4 17 10 : 50 11 : 20 6 4 17 11
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
MM0506-Ariyoshi.ind
51 2005133 Six years of experiences at the U.K. MRC Laboratories, The Gambia, in West Africa Koya ARIYOSHI 130 1965 1992 Jonathan Weber Medical Research Council MRC Laboratories, The Gambia HIV Virologist/Immunologist
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
Title 東 京 歯 科 大 学 研 究 年 報 : 平 成 13 年 度 Journal 東 京 歯 科 大 学 研 究 年 報, (): - URL http://hdl.handle.net/10130/373 Right Posted at the Institutional Resources for Unique Colle Available from http://ir.tdc.ac.jp/
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
untitled
26 9 201491 PL PL PL 1 1 2 3 4 1 1 2 3 4 1,000 10 501003 7 5 6 2 10 1 1 10 2 2 1,000 1,000 50100 50100 50100 50 100 5 6 3 4 3 2 1 10 1100 11,000 1 5001,000 150 1,000 1,000 1,000 90 15001,000 15,000 15,000
日本職業・災害医学会会誌第54巻第6号
274 日本職業 災害医学会会誌 JJOMT Vol. 54, No. 6 図 1 初診時所見 上 左足は足背の全体と踵部以外の足底が III 度熱傷であった 下 右足は足底の踵部から足背外踝部にかけて III 度熱傷であり それ以外は深達性 II 度熱傷であった 図 2 受傷後 19 日目に左足の III 度熱傷のデブリードメンと第 1 趾 の壊死した末節骨 第 2 5 趾の中節骨 1/2 より末梢の切除を行
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
エンジョイ北スポーツ
2772083130 83 1 2 3 4 5 6 7 8 2 2 2 3 3 4 4 6 7 8 1211 53 /15,171 /509 /670 /13,992 2 83130 http://www.kita-city-taikyo.or.jp 83130 http://www.kita-city-taikyo.or.jp 3 68 35 45 4 83130 http://www.kita-city-taikyo.or.jp
VOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Ⅱ Ⅲ Ⅳ Assertive community treatment - Issues from scientific and clinical literature with implications for practice The Impact of Supported Employment and Working on Clinical and
京都 女子 大学現代 社会研 究 33 箱 庭1 箱 庭7 箱 庭3 箱 庭11 箱庭4 Amato, P. R. (1994) Life-span adjustment of children to their parents' divorce. The Future of children: Children and Divorce. 4(1), 143-164. Hetherington,
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
資料３ 危害や迷惑問題等への対応状況
1 2 3 4 16 12 9 1 5 6 7 8 9 10 11 H16 12 91 10 60 30 13 13 16 12 15 16 14 15 16 (1) (2) (3) 17 18 19 20 () 21 HP http://www.ktr.mlit.go.jp/sinrin/dogrun.htm 22 23 14 5 24 25 11 26 Vol.57No.12004 Vol.56No.122003
一般演題（ポスター）
6 5 13 : 00 14 : 00 A μ 13 : 00 14 : 00 A β β β 13 : 00 14 : 00 A 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
日本職業・災害医学会会誌第51巻第5号
Reprint request: TREATMENT FOR CALCANEAL FRACTURE Yumiko ISHIBASHI, Hiroshi HIEDA, Katsuya KANESAKI, Takashi TAMAKI, Yoshimasa HIRAI, Tojiro YANAGI and Yoshifumi KUNO Department of Orthopedic Surgery,
_2009_No5_SEP.ren
ISSN 0389-5254 2009 No.5 SEP JAPAN AIRCRAFT PILOT ASSOCIATION C O N T E N T S No.316 2009 No.5 SEP e 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP 2009 SEP Fly with
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
八ヶ岳の食卓 -flavours from the forest-
11 12 64 65 66 67 68 69 70 71 201 202 203 204 205 206 210 211 212 213 214 215 216 217 366 367 368 373 374 375 386 387 388 389 390 391 432 511 512 513 520 521 522 523 524 525 526 527 528 587 588
11) Kumar, R., et al.: Lancet, 1 : 90, 1973. 12) Baek, S. M., et al.: Ann. Surg., 177: 253, 1973. 13) Beak, S. M., et al.: Ann. Surg., 178 : 605, 1978. 14) Beak, S. M., et al.: Surgery, 77: 632, 1975.
1 913 10301200 A B C D E F G H J K L M 1A1030 10 : 45 1A1045 11 : 00 1A1100 11 : 15 1A1115 11 : 30 1A1130 11 : 45 1A1145 12 : 00 1B1030 1B1045 1C1030
1 913 9001030 A B C D E F G H J K L M 9:00 1A0900 9:15 1A0915 9:30 1A0930 9:45 1A0945 10 : 00 1A1000 10 : 15 1B0900 1B0915 1B0930 1B0945 1B1000 1C0900 1C0915 1D0915 1C0930 1C0945 1C1000 1D0930 1D0945 1D1000
54-4.ren
200454 4 604-619 1,3) 1,3) 1,3) 1) 1) 1) 2) 1) 2) 3) 2004.8.1 1) 2) 1) 3) 1 50 4) 2 BC 581 3 4) 4 54 4 2004.8.1 1 1 2 3 3 7 3 1 4 5 5 7 2 3 1 54 4 10 15 4 4) 5 1 6 ) 7) 7) 2004.8.1 8) 8) 8) 8 ) 2 9) c
Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe
Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhei Kobayashi*2, Mamoru Nishimuta*2, Michiyuki Shimizu*3,
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium